AEterna reports on its phase II trial of neovastat.
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy*; D014020:Tissue Extracts / Q000627:therapeutic use*
D020533:Angiogenesis Inhibitors; D014020:Tissue Extracts; C111481:shark cartilage extract